Prevalence of severe infections, gingivitis, and leukemic transformation by ELA2 genotype
. | SCN group . | . | . | CN group . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | NN . | NM . | P . | NN . | NM . | P . | ||||
| No. patients | 35 | 19 | — | 15 | 12 | — | ||||
| Period of follow-up without G-CSF* | 9.4 | 4.1 | — | 7.4 | 8.2 | — | ||||
| Prevalence of infections, n | ||||||||||
| All infections (%) | 15 (42) | 16 (84) | .003 | 3 (20) | 9 (75) | .006 | ||||
| Omphalitis | 3 | 4 | NS | 0 | 1 | NS | ||||
| Cellulitis | 7 | 11 | .006 | 1 | 4 | NS | ||||
| Perianal abscess | 5 | 5 | NS | 0 | 2 | NS | ||||
| Pneumonia | 6 | 11 | .003 | 2 | 2 | NS | ||||
| Sepsis | 1 | 3 | NS | 1 | 2 | NS | ||||
| Aspergillosis | 3 | 2 | NS | 3 | 1 | NS | ||||
| Prevalence of gingivitis, n (%) | 17 (49) | 11 (58) | NS | 5 (33) | 5 (42) | NS | ||||
| Prevalence of leukemic transformation, n (%) | 0 | 4 (21) | .04 | 0 | 0 | — | ||||
. | SCN group . | . | . | CN group . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | NN . | NM . | P . | NN . | NM . | P . | ||||
| No. patients | 35 | 19 | — | 15 | 12 | — | ||||
| Period of follow-up without G-CSF* | 9.4 | 4.1 | — | 7.4 | 8.2 | — | ||||
| Prevalence of infections, n | ||||||||||
| All infections (%) | 15 (42) | 16 (84) | .003 | 3 (20) | 9 (75) | .006 | ||||
| Omphalitis | 3 | 4 | NS | 0 | 1 | NS | ||||
| Cellulitis | 7 | 11 | .006 | 1 | 4 | NS | ||||
| Perianal abscess | 5 | 5 | NS | 0 | 2 | NS | ||||
| Pneumonia | 6 | 11 | .003 | 2 | 2 | NS | ||||
| Sepsis | 1 | 3 | NS | 1 | 2 | NS | ||||
| Aspergillosis | 3 | 2 | NS | 3 | 1 | NS | ||||
| Prevalence of gingivitis, n (%) | 17 (49) | 11 (58) | NS | 5 (33) | 5 (42) | NS | ||||
| Prevalence of leukemic transformation, n (%) | 0 | 4 (21) | .04 | 0 | 0 | — | ||||
NS indicates not significant; NN genotype, patient with no ELA2 mutation; NM genotype, patient with a heterozygous ELA2 mutation; and —, not applicable.
Expressed as the median time in years